Patent Issued for Siglec-9-neutralizing antibodies (USPTO 11623954).
In: Pharma Business Week, 2023-05-01, S. 3047-3047
serialPeriodical
Zugriff:
Chem. Biol. 10:69-77 reported that blocking anti-Siglec-7 antibodies inhibited the Siglec-7 mediated protection of tumor target cells from lysis by NK cells. Optionally, the Siglec-9 polypeptide is expressed at the surface of a cell, e.g., an effector lymphocyte, an NK cell, e.g., a primary NK cell, a CD56 SP dim sp NK cell from a human individual. In one embodiment, the Siglec inhibitor is an antibody or antibody fragment that is capable of bivalent binding to a human Siglec-9 protein (the inhibitor comprises two antigen binding domains that each are capable of binding to a human Siglec-9 protein). "In one aspect, the present invention arises, inter alia, from the discovery of antibodies that specifically bind human Siglec-9 and that enhance the activity (e.g. cytotoxicity) of NK cells (e.g. primary NK cells) towards a sialic-acid ligand-bearing target cell. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Siglec-9-neutralizing antibodies (USPTO 11623954).
|
---|---|
Zeitschrift: | Pharma Business Week, 2023-05-01, S. 3047-3047 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|